Avenue Therapeutics, Inc. (ATXI)
| Market Cap | 840.55K -15.3% |
| Revenue (ttm) | n/a |
| Net Income | -2.78M |
| EPS | -0.86 |
| Shares Out | 3.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Open | 0.2700 |
| Previous Close | 0.2551 |
| Day's Range | 0.2551 - 0.2700 |
| 52-Week Range | 0.1500 - 0.9699 |
| Beta | -0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. [Read more]
Financial Performance
Financial StatementsNews
Avenue Therapeutics Quarterly report: Q2 2026
Avenue Therapeutics has published its Q2 2026 quarterly earnings report on August 7, 2026.
Avenue Therapeutics Quarterly report: Q1 2026
Avenue Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Avenue Therapeutics Annual report: Q4 2025
Avenue Therapeutics has published its Q4 2025 annual report on March 30, 2026.
Avenue Therapeutics enters worldwide license agreement for ATX-04
Avenue Therapeutics (ATXI) announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 in clinical development for th...
Avenue Therapeutics Transcript: AGM 2025
The 2025 Annual Meeting confirmed a quorum, elected all nominated directors for the next term, and ratified KPMG LLP as the independent auditor for 2025. Stockholders were invited to submit questions for follow-up after the meeting.
Avenue Therapeutics Proxy statement: Proxy Filing
Avenue Therapeutics filed a proxy statement on December 5, 2025, providing details for shareholder voting and corporate governance matters.
Avenue Therapeutics Quarterly report: Q3 2025
Avenue Therapeutics has published its Q3 2025 quarterly earnings report on November 13, 2025.
Avenue Therapeutics announces Baergic Bio acquisition by Axsome
Avenue Therapeutics (ATXI) subsidiary, Baergic Bio announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics (AXSM), including the global rights to BAER-101...
Avenue Therapeutics Quarterly report: Q2 2025
Avenue Therapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.
Avenue Therapeutics Quarterly report: Q1 2025
Avenue Therapeutics has published its Q1 2025 quarterly earnings report on May 14, 2025.
Avenue Therapeutics Annual report: Q4 2024
Avenue Therapeutics has published its Q4 2024 annual report on March 31, 2025.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Annexon (ANNX), 807% surge in interest Avenue Therapeutic...
Avenue Therapeutics files $35M mixed securities shelf
17:16 EST Avenue Therapeutics (ATXI) files $35M mixed securities shelf
Avenue Therapeutics Registration statement: Registration Filing
Avenue Therapeutics filed a registration statement on December 4, 2024, providing details about a securities offering with the SEC.
Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)
As of September 30 cash and cash equivalents totaled $2.6M , compared to $4.9M at June 30 and $1.8 M at December 31, 2023, a decrease of $2.3M compared to…
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulba...
Avenue Therapeutics Quarterly report: Q3 2024
Avenue Therapeutics has published its Q3 2024 quarterly earnings report on November 14, 2024.
Avenue Therapeutics Earnings release: Q3 2024
Avenue Therapeutics released its Q3 2024 earnings on November 14, 2024, summarizing the period's financial results.
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
Avenue Therapeutics to Participate in Upcoming Investor Conferences
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –
Avenue Therapeutics Quarterly report: Q2 2024
Avenue Therapeutics has published its Q2 2024 quarterly earnings report on August 9, 2024.
Avenue Therapeutics Earnings release: Q2 2024
Avenue Therapeutics released its Q2 2024 earnings on August 9, 2024, summarizing the period's financial results.
Avenue Therapeutics Transcript: AGM 2024
The meeting confirmed a quorum, approved the election of directors, ratified KPMG LLP as auditors for 2024, and passed an amendment to the 2015 Incentive Plan increasing authorized shares and extending its term. Attendees could submit questions online.
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...